AUSTIN, Texas, April 16, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML - News), a leading molecular diagnostics company, has received a notice of allowance from the United States Patent and Trademark Office for a patent, "Biomarkers for Ovarian Cancer."
The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient management.
This represents the fifteenth biomarker patent granted or allowed for Vermillion, four of which support the company's ovarian cancer franchise and its flagship product, OVA1®.
"Our innovative biomarker research continues to build Vermillion's platform of proprietary diagnostic tools, which is supported by key patents," said Donald Munroe, Ph.D., the company's chief science officer and VP of research & development. "We believe these tools represent the best diagnostic tools available today in the diagnosis and management of ovarian cancer, which is the leading cause of gynecologic cancer mortality."
About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(1) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(2) As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.
Citings: 1) Ueland, FR, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011 2) Ueland, FR, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011 3) Miller R, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011
About Vermillion
Vermillion, Inc. (NASDAQ: VRML - News) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com.
Market Data 
Markets 
AI
